Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.
Eckmann K, Michaud LB, Rivera E, Madden TL, Esparza-Guerra L, Kawedia J, Booser DJ, Green MC, Hortobagyi GN, Valero V. Eckmann K, et al. Among authors: green mc. J Oncol Pharm Pract. 2014 Apr;20(2):120-9. doi: 10.1177/1078155213480536. Epub 2013 May 14. J Oncol Pharm Pract. 2014. PMID: 23676510
Neoadjuvant chemotherapy for operable breast cancer.
Green M, Hortobagyi GN. Green M, et al. Oncology (Williston Park). 2002 Jul;16(7):871-84, 889; discussion 889-90, 892-4, 897-8. Oncology (Williston Park). 2002. PMID: 12164555 Free article. Review.
Adjuvant chemotherapy for breast cancer.
Green MC, Hortobagyi GN. Green MC, et al. Langenbecks Arch Surg. 2002 Jul;387(3-4):109-116. doi: 10.1007/s00423-002-0288-8. Langenbecks Arch Surg. 2002. PMID: 12269263 Review.
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Symmans WF, et al. Among authors: green mc. Cancer. 2003 Jun 15;97(12):2960-71. doi: 10.1002/cncr.11435. Cancer. 2003. PMID: 12784330 Free article.
Neoadjuvant chemotherapy.
Green MC, Esteva FJ, Hortobagyi GN. Green MC, et al. Breast Dis. 2004;21:23-31. doi: 10.3233/bd-2004-21104. Breast Dis. 2004. PMID: 15687719 Review. No abstract available.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Buzdar AU, et al. Among authors: green mc. J Clin Oncol. 2005 Jun 1;23(16):3676-85. doi: 10.1200/JCO.2005.07.032. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738535 Clinical Trial.
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Rouzier R, et al. Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20. doi: 10.1073/pnas.0408974102. Epub 2005 May 24. Proc Natl Acad Sci U S A. 2005. PMID: 15914550 Free PMC article.
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Green MC, et al. J Clin Oncol. 2005 Sep 1;23(25):5983-92. doi: 10.1200/JCO.2005.06.232. Epub 2005 Aug 8. J Clin Oncol. 2005. PMID: 16087943 Clinical Trial.
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Buzdar AU, et al. Among authors: green mc. Clin Cancer Res. 2007 Jan 1;13(1):228-33. doi: 10.1158/1078-0432.CCR-06-1345. Clin Cancer Res. 2007. PMID: 17200359 Clinical Trial.
162 results